CD38 and plasma cell myeloma: Adapting to the current standards of care in myeloma, proposed regimens for fit, transplant-eligible patients would be induction therapy with an anti-CD38 monoclonal antibody, proteasome inhibitor, lenalidomide, and dexamethasone with or without cyclophosphamide, followed by at least one autologous transplant and prolonged maintenance with an anti-CD38, proteasome inhibitor, and lenalidomide.